Hansa Biopharma to participate in LSX Congress USA in Boston
Idag, 17:15
Hansa Biopharma to participate in LSX Congress USA in Boston
Lund, Sweden, September 21, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Fredrik Röök, VP Business Development at Hansa Biopharma, will participate in the panel discussion “Breaking into New Markets: Strategies for Global Biopharma Expansion” at LSX Congress USA in Boston at 11:00 a.m. EST on Wednesday, September 23, 2026.
If you are interested in meeting with Hansa’s management, please contact Hansa Biopharma at ir@hansabiopharma.com.
Event: Panel discussion at LSX Congress USA
Title: Breaking into New Markets: Strategies for Global Biopharma Expansion
Date, Time and Place: Wednesday 23 September, 11:00 EST, Boston
Moderator: Pankaj Oza, Managing Partner, Blue Matter Consulting
Speakers:
- Fredrik Röök, VP Business Development, Hansa Biopharma
- Mike Patten, Chief Strategy Officer, Harbour BioMed
- Abhijit Bhatia, Chief Operating Officer, Rakuten Medical
- Suguna Rachakonda, SVP, Strategy & BD, Micro CRISPR
--- ENDS ---
Contacts for more information:
Adam Cutler, Chief Financial Officer
IR@hansabiopharma.com
Kerstin Falck, VP Global Corporate Affairs
media@hansabiopharma.com
Notes to editors
About Hansa Biopharma
Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company developing and commercializing novel immunomodulatory therapies to transform care for patients with acute or complex immune disorders. Hansa’s proprietary IgG-cleaving enzyme technology platform addresses serious unmet medical needs in transplantation, gene therapy and autoimmune diseases. The company’s portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients, and HNSA-5487, a next-generation IgG-cleaving molecule that will be developed for Guillain-Barré Syndrome (GBS). Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com and follow us on LinkedIn.
©2026 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, Idefirix®, and Idefirix flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.
Ämnen i artikeln
Hansa Biopharma to participate in LSX Congress USA in Boston
Idag, 17:15
Hansa Biopharma to participate in LSX Congress USA in Boston
Lund, Sweden, September 21, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Fredrik Röök, VP Business Development at Hansa Biopharma, will participate in the panel discussion “Breaking into New Markets: Strategies for Global Biopharma Expansion” at LSX Congress USA in Boston at 11:00 a.m. EST on Wednesday, September 23, 2026.
If you are interested in meeting with Hansa’s management, please contact Hansa Biopharma at ir@hansabiopharma.com.
Event: Panel discussion at LSX Congress USA
Title: Breaking into New Markets: Strategies for Global Biopharma Expansion
Date, Time and Place: Wednesday 23 September, 11:00 EST, Boston
Moderator: Pankaj Oza, Managing Partner, Blue Matter Consulting
Speakers:
- Fredrik Röök, VP Business Development, Hansa Biopharma
- Mike Patten, Chief Strategy Officer, Harbour BioMed
- Abhijit Bhatia, Chief Operating Officer, Rakuten Medical
- Suguna Rachakonda, SVP, Strategy & BD, Micro CRISPR
--- ENDS ---
Contacts for more information:
Adam Cutler, Chief Financial Officer
IR@hansabiopharma.com
Kerstin Falck, VP Global Corporate Affairs
media@hansabiopharma.com
Notes to editors
About Hansa Biopharma
Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company developing and commercializing novel immunomodulatory therapies to transform care for patients with acute or complex immune disorders. Hansa’s proprietary IgG-cleaving enzyme technology platform addresses serious unmet medical needs in transplantation, gene therapy and autoimmune diseases. The company’s portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients, and HNSA-5487, a next-generation IgG-cleaving molecule that will be developed for Guillain-Barré Syndrome (GBS). Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com and follow us on LinkedIn.
©2026 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, Idefirix®, and Idefirix flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.
Ämnen i artikeln
Marknadsöversikt
1 DAG %
Senast
1 mån
